Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Working tool

Storage and in-use stability lookup

What the Institute has assessed for a compound at a given state and temperature, and what it declines to claim.

§1Lookup

Storage and in-use stability

§2Why so many entries say nothing is supported

An in-use period requires a stability-indicating method — one demonstrated by forced-degradation study to separate the intact compound from its degradation products — applied to the actual presentation, over the claimed period, monitoring purity, aggregate content, pH and appearance. The Institute has identified no such data for any research-supply presentation of any compound in its set.

In the absence of that, a storage recommendation is an extrapolation from formulation science. The Institute makes the extrapolation where the pharmacology is unambiguous, as with frozen storage of a dry lyophilisate, and declines it where it is not, as with any reconstituted solution. The reasoning is at CEI-MS-21 and in the in-use stability review.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.